Komipharm International Australia Pty. Ltd. announced that it expects to receive AUD 3.58605 million in funding from Komipharm International Co., Ltd.
December 17, 2021
Share
Komipharm International Australia Pty. Ltd. announced a private placement of 23,907 common shares at an issue price of AUD 150 per share for gross proceeds of AUD 3,586,050 on December 17, 2021. The transaction include participation from returning investor Komipharm International Co., Ltd. The transaction was approved by the board of directors of the company. The expected closing date is on December 23, 2021. The securities issued through capital increase method.
Komipharm International Co Ltd is a Korea-based company principally engaged in the development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The Companyâs main products include veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle, vaccines for infectious bronchitis and Newcastle disease, and canine respiratory infection killed vaccines, and veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis and bacterial diseases for livestock. The Company also engages in research and development of anticancer drugs and cancer pain-relieving agents. In addition, the Company provides services such as pathological biopsies, serum tests, and bacteria tests.
KOMIPHARM INTERNATIONAL CO., LTD. 
